Drug Solutions Pharm Tech

In this episode of the Drug Solutions podcast, Grant Playter, Associate Editor, speaks with Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023. Topics of discussion include key areas of investment, where investment is occurring and why, and how the industry is adjusting to post-COVID regulatory and supply chain changes.

In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, talks to Hanns-Christian Mahler, CEO and board member, and Andrea Allmendinger, chief scientific officer, both at ten23 health about some of the hurdles facing developers and manufacturers of biological therapies. Hanns-Christian and Andrea take a closer look at some of the solutions being used within industry to overcome these challenges and focus on the issue of sustainability within this sphere. Finally, they touch upon some of the other potentially important future trends that will impact biologic drug development and manufacturing.

Following disruption in the bio/pharmaceutical supply chain as a result of the COVID pandemic, the outsourcing industry has learned to adapt and push forward in a climate that is dyamically different. In this Drug Solutions podcast episode, Pharmaceutical Technology® spoke with Gil Roth, president of the Pharma & Biopharma Outsourcing Association (PBOA), and Tara Dougal, content director, Pharma portfolio, Informa Markets, on the current challenges facing the outsourcing industry today as well how contract service providers are tackling sustainability and other big trends in the industry.

SPONSOR:
Lonza

In this episode of the Drug Solutions podcast, Jill Murphy, Editor, talks to Lon Johnson, VP of Sales and Marketing at Colbert Packaging Corporation, about drug packaging solutions, sustainable options for companies to move towards, EPR laws, and the challenges of transitioning to more renewable packaging options.

Sponsor: Colbert Packaging

In this episode of the Drug Solutions podcast, Jill Murphy, Editor, talks to Adam C. Fisher, PhD, director of Science Staff and Immediate Office/Office of Pharmaceutical Quality at the Center for Drug Evaluation and Research/FDA, about point of care, patient manufacturing, and new innovative technologies in the industry.

In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, talks to Rhonda Henry, President of Emmes’ BioPharma Group, and Adam Mendizabal, VP and Director of Emmes’ Cell and Gene Therapy Center, about the role contract research organizations (CROs) play in cell and gene therapy development. Rhonda and Adam will discuss the key factors and solutions driving growth in the CRO market with a particular emphasis on cell and gene therapies entering development pipelines, and will address some of the challenges facing the industry and best practices to ensure these limitations are overcome.

SPONSOR: Baxter BioPharma Solutions